Tocilizumab for calciphylaxis pain and sores
Treatments studied
Part of Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a drug called tocilizumab (which calms inflammation) to see if it helps people with calciphylaxis, a painful skin condition linked to kidney disease. The drug might reduce pain and improve healing of skin sores.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with calciphylaxis (painful skin sores and tissue damage) by a skin specialist or surgeon.
- You have advanced kidney disease, either on dialysis or with severely reduced kidney function.
- You are willing to have blood tests to monitor your health and for research.
- You agree to use effective birth control during the study and for 3 months after the last dose.
- You have not had an active serious infection, tuberculosis, or hepatitis B or C recently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects and stores information from people with calciphylaxis, a serious condition that causes painful skin lesions. It may help researchers learn more about the disease and improve future care.
This trial tests an investigational drug called EPN-701 for people with calciphylaxis, a painful condition that causes skin ulcers and often affects those on dialysis. The study aims to see if the drug can reduce pain and improve the condition.
This Phase 3 study is for adults on regular dialysis who have a new calciphylaxis ulcer. It tests a better way to give and use treatment guidance so ulcers may improve with clearer, more consistent care.
This study looks at a rare condition called calciphylaxis (hardening of small blood vessels) that can happen in people with chronic kidney disease. It aims to learn more about what causes it and how to help those affected.
This early-phase study tests a stem cell therapy made from amniotic (placenta) tissue for people with calciphylaxis. If you qualify, the goal is to see whether this treatment is safe and potentially helpful for this rare, painful condition.
This trial studies whether a treatment called rheopheresis, added to standard care, can help people with calciphylaxis whose skin wounds are getting worse. It may be considered when ulcers or dead (necrotic) skin appear despite conventional treatment.
Hear when a new Calciphylaxis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.